{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["40"],"submitter":["Khawaja T"],"pubmed_abstract":["<h4>Background</h4>Though the co-prevalence of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized, the role of transcatheter aortic valve replacement (TAVR) in patients with CA remains unclear.<h4>Methods</h4>The National Readmission Dataset (2016-18) and ICD-10 codes were used to identify those with CA and AS, in conjunction with TAVR status. The primary outcome was a composite of heart failure (HF) readmissions and all-cause mortality. All outcomes were followed up to 1-year with a median follow up time 172-days. Kaplan-Meier curves and multivariate cox-proportional hazard regression were used for time-to-event analysis.<h4>Results</h4>Of 1,127 CA patients, 92 (8.2%) had undergone TAVR. Patients with CA who received TAVR were younger and more commonly had corona"],"journal":["International journal of cardiology. Heart & vasculature"],"pagination":["101008"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8938882"],"repository":["biostudies-literature"],"pubmed_title":["Transcatheter aortic valve replacement in patients with aortic stenosis and cardiac amyloidosis."],"pmcid":["PMC8938882"],"pubmed_authors":["Jain A","Najeeb Osman M","Khawaja T","Arora N","Jaswaney R","Yoon S","Attizzani GF","Arora S","Augusto Palma Dallan L","Filby SJ"],"additional_accession":[]},"is_claimable":false,"name":"Transcatheter aortic valve replacement in patients with aortic stenosis and cardiac amyloidosis.","description":"<h4>Background</h4>Though the co-prevalence of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized, the role of transcatheter aortic valve replacement (TAVR) in patients with CA remains unclear.<h4>Methods</h4>The National Readmission Dataset (2016-18) and ICD-10 codes were used to identify those with CA and AS, in conjunction with TAVR status. The primary outcome was a composite of heart failure (HF) readmissions and all-cause mortality. All outcomes were followed up to 1-year with a median follow up time 172-days. Kaplan-Meier curves and multivariate cox-proportional hazard regression were used for time-to-event analysis.<h4>Results</h4>Of 1,127 CA patients, 92 (8.2%) had undergone TAVR. Patients with CA who received TAVR were younger and more commonly had corona","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-04T23:34:07.661Z","creation":"2025-04-04T23:34:07.661Z"},"accession":"S-EPMC8938882","cross_references":{"pubmed":["35330979"],"doi":["10.1016/j.ijcha.2022.101008"]}}